A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

With NCI Director Anthony Letai in Milan supporting his daughter, Julie, at the 2026 Winter Olympics, Douglas R. Lowy, principal deputy director of NCI, took on the job of delivering detailed remarks and fielding questions at the inaugural meeting of the NCAB’s ad hoc working group on Extramural Research Concepts and Programs.

February 18, 2026

NCI

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.

NCAB ad hoc group approves seven new, reissue concepts

The National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs on Feb. 6 voted to approve four new and three reissue concepts.

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors

The new ad hoc working group of the National Cancer Advisory Board will play a key role in shaping NCI’s extramural priorities, NCI Director Anthony Letai said at the group’s inaugural meeting Feb. 6.

February 06, 2026

Vol.52 No.05

By Claire Marie Porter

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

YOU MAY BE INTERESTED IN

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

NCAB ad hoc group approves seven new, reissue concepts

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors

Renew today!

Subscriber content

Never miss an issue!

Login

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

YOU MAY BE INTERESTED IN

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades agoLowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

NCAB ad hoc group approves seven new, reissue concepts

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural researchThe group replaced the NCI Board of Scientific Advisors

Never miss an issue!

Login

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors